###### Key messages

What is already known about this subject?
=========================================

-   Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of vaccine-preventable infections and associated complications.

-   Vaccination may be less efficacious in (subgroups of) patients with AIIRD and could potentially lead to exacerbation of underlying disease.

-   Evidence-based recommendations of the EULAR for vaccination of adult patients with AIIRD were published in 2011.

What does this study add?
=========================

-   This systematic literature review summarises available evidence on efficacy, immunogenicity and safety of vaccination in AIIRD since October 2009, providing a basis for updated EULAR recommendations.

How might this impact on clinical practice?
===========================================

-   The aim of the updated recommendations is to aid health professionals dealing with questions regarding vaccination in patients with AIIRD, whereby reducing infection-related morbidity and mortality.

Introduction {#s1}
============

Infectious diseases and associated complications comprise an important cause of morbidity and mortality in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Increased susceptibility to infectious diseases in these patients is most likely due to an immunomodulating effect of the disease itself and/or by use of immunosuppressive medications.[@R1]

Vaccination is generally regarded as a safe, efficacious and low-cost method for preventing certain infections. However, vaccination may be less efficacious in (subgroups of) patients with AIIRD, as a result of their immunosuppressed state, and, moreover, could potentially lead to exacerbation of the underlying AIIRD.

In 2011, evidence-based recommendations for vaccination in patients with AIIRD were published. They were formulated by an EULAR task force to aid health professionals dealing with questions regarding vaccination in patients with AIIRD in daily clinical practice, with the aim of reducing infection-related morbidity and mortality in these patients.[@R2] The authors stated that the recommendations needed to be updated on a regular basis as new evidence becomes available.[@R2] Towards this end, the League commissioned another multidisciplinary task force with the purpose of formulating up-to-date recommendations for vaccination in patients with AIIRD.

The current report presents the results of an SLR on efficacy, immunogenicity and safety of vaccination in adult patients with AIIRD, including those using immunomodulating agents. Together with the results of an SLR on incidence and prevalence of VPIs in patients with AIIRD,[@R1] the current SLR provided the task force with a basis for updating the recommendations.[@R3]

Methods {#s2}
=======

The work was performed in accordance with the 2014 EULAR standard operating procedures for EULAR-endorsed recommendations.[@R4]

The expert committee first formulated four main research questions ([Box 1](#B1){ref-type="boxed-text"}), based on the 2011 version of the recommendations. The current review reports on the SLR results of three of these four questions, which include the topics of efficacy, immunogenicity and safety of vaccination in adult patients with AIIRD (including those receiving immunosuppressive agents) and the effect of vaccinating their household members on the occurrence of VPIs in both patients and their household members (including newborns). The efficacy of vaccination was defined as the capacity to prevent infections, while the immunogenicity of vaccination refers to the capacity to induce vaccine-specific humoral and/or cellular immune responses. Safety of vaccination in the AIIRD population was determined by the assessment of both the occurrence of adverse effects and the influence on the underlying disease.[@R1]

###### Research questions

-   What is the incidence or prevalence of vaccine-preventable infections (VPI) in adult patients with AIIRD?\*

-   What is the efficacy, immunogenicity and safety of available vaccines in adult patients with AIIRD?

-   Are vaccines efficacious and immunogenic in adult patients with AIIRD, treated with immunosuppressive agents and disease-modifying antirheumatic drugs?

-   What is the effect of vaccinating household contacts of patients with AIIRD on the occurrence of VPI in both patients and household members (including newborns)?

\* The systematic literature review covering research question 1 has been submitted for publication separately.[@R1]

AIIRD, autoimmune inflammatory rheumatic disease(s).

Next, the research questions were adapted according to the PICO-method (population-intervention-comparison-outcome). Population, intervention, comparison and outcome definitions were combined and adapted to be used as search terms ([table 1](#T1){ref-type="table"}). Medline (via Pubmed), Embase and the Cochrane Library were searched from October 2009 to August 2018. Meta-analyses, randomised trials, cohort studies and case series with at least five participants were eligible. Only English articles on adult patients (≥18 years) were included. Papers with non-original data, case reports, case series with less than five patients, abstracts presented in scientific meetings, and papers included in the previous version of these recommendations were excluded. Papers that were not retrieved in the search, but were relevant in the opinion of the committee, could be added. See [figure 1](#F1){ref-type="fig"} for the flow chart displaying the search strategy for PICO 2 and 3. For some of the AIIRD, immunomodulating agents and vaccines (diphteria, pertussis, measles, mumps, rubella, *Neisseria meningitides, Haemophilus influenzae* B and typhoid fever vaccine) that were included in the literature search, no relevant articles were retrieved. No relevant articles were retrieved in the search on the effect of vaccinating household members of patients with AIIRD (research question 4).

![Flow chart displaying the search strategy for PICO 2 and 3. DMARDs, disease-modifying antirheumatic drugs; IS, immunosuppressives; PICO, population-intervention-comparison-outcome.](rmdopen-2019-001035f01){#F1}

###### 

Formulation of PICO-questions

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------
  Q2: What is the efficacy, immunogenicity and safety of available vaccines in adult patients with AIIRD?\                                                                                                                                                                               
  Population: patients with AIIRD\*\                                                                                                                                                                                                                                                     
  Intervention: immunisation/vaccination with vaccines suitable for adults\*\*\                                                                                                                                                                                                          
  Comparison: healthy controls, non-vaccinated patients with AIIRD or none\                                                                                                                                                                                                              
  Outcome: efficacy (prevention of vaccine-preventable disease), immunogenicity (laboratory markers for vaccine efficacy, eg, seroprotection/seroconversion) and safety (effect on the underlying autoimmune disease or adverse effects from vaccination)                                

  Q3: Are vaccines efficacious and immunogenic in adult patients with AIIRD, treated with immunosuppressive agents and disease-modifying antirheumatic drugs (DMARDs)?\                                                                                                                  
  Population: patients with AIIRD\* using immunomodulating agents\*\*\*\                                                                                                                                                                                                                 
  Intervention: immunisation/vaccination with vaccines suitable for adults\*\*\                                                                                                                                                                                                          
  Comparison: healthy controls, patients with AIIRD not using analysed agents or none\                                                                                                                                                                                                   
  Outcome: efficacy (prevention of vaccine-preventable disease), immunogenicity (laboratory markers for vaccine efficacy, eg, seroprotection/seroconversion)                                                                                                                             

  Q4: What is the effect of vaccinating household members of patients with AIIRD on the occurrence of VPI in both the patients and household members (including newborns)?\                                                                                                              
  Population: patients with AIIRD\*\                                                                                                                                                                                                                                                     
  Intervention: immunisation/vaccination of household contacts of patients with AIIRD with vaccines suitable for children and adults\*\*\                                                                                                                                                
  Comparison: patients with AIIRD with non-vaccinated household members\                                                                                                                                                                                                                 
  Outcome: incidence of VPI in patients with AIIRD/safety of household vaccine for patients with AIIRD                                                                                                                                                                                   

  **\* AIIRD**                                                                                                                                                                                                                                              **\*\* Vaccines**            **\*\*\* Immunomodulating agents**

  Rheumatoid arthritis                                                                                                                                                                                                                                      Influenza                    Glucocorticosteroids

  Systemic lupus erythematosus                                                                                                                                                                                                                              Tetanus toxoid               Methotrexate

  Antiphospholipid syndrome                                                                                                                                                                                                                                 Diphtheria                   Sulfasalazine

  Adult Still's disease                                                                                                                                                                                                                                     Pertussis                    Leflunomide

  Systemic sclerosis                                                                                                                                                                                                                                        Measles                      Hydroxychloroquine

  Sjögren syndrome                                                                                                                                                                                                                                          Mumps                        Azathioprine

  Mixed connective tissue diseases                                                                                                                                                                                                                          Rubella                      Mycophenolic preparation

  Relapsing polychondritis                                                                                                                                                                                                                                  Varicella-zoster virus       Ciclosporine

  Giant cell arteritis                                                                                                                                                                                                                                      Human papillomavirus         Tacrolimus

  Polymyalgia rheumatica                                                                                                                                                                                                                                    *Streptococcus pneumoniae*   Cyclophosphamide

  Takayasu arteritis                                                                                                                                                                                                                                        Hepatitis A                  Rituximab

  Polyarteritis nodosa                                                                                                                                                                                                                                      Hepatitis B                  Belimumab

  ANCA-associated vasculitis                                                                                                                                                                                                                                *Neisseria meningitidis*     Abatacept

  Microscopic polyangiitis                                                                                                                                                                                                                                  *Haemophilus influenzae B*   TNFα blocking agents

  Granulomatosis with polyangiitis                                                                                                                                                                                                                          Tickborne encephalitis       Infliximab

  Eosinophilic granulomatosis with polyangiitis                                                                                                                                                                                                             Typhoid fever                Etanercept

  Behçet's disease                                                                                                                                                                                                                                          Yellow fever                 Adalimumab

  Anti-GBM disease                                                                                                                                                                                                                                                                       Certolizumab

  Cryoglobulinaemic syndrome                                                                                                                                                                                                                                                             Golimumab

  Polymyositis                                                                                                                                                                                                                                                                           Anti-IL-6 agents

  Dermatomyositis                                                                                                                                                                                                                                                                        Tocilizumab

  Clinically amyotrophic dermatomyositis                                                                                                                                                                                                                                                 Sarilumab

  Inclusion body myositis                                                                                                                                                                                                                                                                Anti-IL-17 agents

  Antisynthetase syndrome                                                                                                                                                                                                                                                                Secukinumab

  Eosinophilic myositis                                                                                                                                                                                                                                                                  Ixekizumab

  Eosinophilic fasciitis                                                                                                                                                                                                                                                                 Anti-IL-1 agents

  Spondyloarthropathies                                                                                                                                                                                                                                                                  Canakinumab

  Periodic fever syndromes                                                                                                                                                                                                                                                               Anakinra

  Familial Mediterranean fever                                                                                                                                                                                                                                                           Rilonacept

  TNF-receptor associated syndrome (TRAPS)                                                                                                                                                                                                                                               Apremilast

  Cryopyrin associated periodic syndrome (CAPS)                                                                                                                                                                                                                                          Tofacitinib

                                                                                                                                                                                                                                                                                         Baricitinib
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------

AIIRD, autoimmune inflammatory rheumatic disease(s); ANCA, antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; IL, interleukin; PICO, population-intervention-comparison-outcome; TNF, tumour necrosis factor; VPI, vaccine-preventable infection.

Data analysis was performed by CR, VF, MH, SvA and OE. The following information was retrieved from all included articles: name of first author, year of publication, country where the study was performed, years of data inclusion, type of study, vaccine used, addition of adjuvant, type of AIIRD, number of participants, age and sex of participants, disease duration, time of follow-up, medication used and outcome of vaccination (efficacy, immunogenicity and/or safety). The articles were critically assessed ([online supplementary file S6](#SP2){ref-type="supplementary-material"}---included articles and critical appraisal) by applying tools from the Cochrane Library ([online supplementary file S7](#SP3){ref-type="supplementary-material"}---critical appraisal criteria) and given a level of evidence based on the Oxford Centre for Evidence-based Medicine approach ([table 2](#T2){ref-type="table"}). Discrepancies between reviewers were resolved by consensus. The final recommendations were graded according to the level of evidence of the underlying articles ([table 3](#T3){ref-type="table"}).[@R5]
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###### 

Oxford Centre for Evidence-Based Medicine---levels of evidence

  Level   
  ------- ------------------------------------------------------------------------------------------------------------------
  1a      Systematic review (with homogeneity) of RCTs
  1b      Individual RCT (with narrow CI)
  1c      'All or none'
  2a      Systematic review (with homogeneity) of cohort studies
  2b      Individual cohort study (including low-quality RCT)
  2c      'Outcomes' research, ecological studies
  3a      Systematic review (with homogeneity) of case-control studies
  3b      Individual case-control study
  4       Case series (and poor quality cohort and case-control studies)
  5       Expert opinion without explicit critical appraisal, or based on physiology, bench research of 'first principles'

RCT, randomised controlled trial.

###### 

Grades of recommendation

  Grade   
  ------- -----------------------------------------------------------------------------------
  A       Consistent level 1 studies
  B       Consistent level 2 or 3 studies or extrapolations from level 1 studies
  C       Level 4 studies or extrapolations from level 2 or 3 studies
  D       Level 5 evidence or troublingly inconsistent or inconclusive studies of any level

Results {#s3}
=======

Influenza vaccination {#s3-1}
---------------------

### Efficacy---immunogenicity---safety {#s3-1-1}

Up to the previous recommendations, one study addressed the issue of efficacy of influenza vaccination in patients with AIIRD.[@R6] Immunogenicity of the vaccine had been evaluated in 26 studies, mainly including patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA).[@R7] Most of these studies demonstrated similar rates of immunogenicity among patients and healthy controls (HC), except for the studies in patients treated with rituximab, whose responses were severely impaired.[@R12]

From the previous recommendations up to August 2018, seven meta-analyses and 50 other studies have been published on efficacy, immunogenicity and safety of influenza vaccination, including the 2009 pandemic H1N1 influenza strain vaccine, in patients with AIIRD ([table 4](#T4){ref-type="table"} for seasonal trivalent and [table 5](#T5){ref-type="table"} for monovalent pandemic influenza vaccination).

###### 

Efficacy, immunogenicity and safety of trivalent influenza vaccination in patients with AIIRD (October 2009--August 2018)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author +ref.             Year   Study design                      No. cases                                                                                               Efficacy                                                                                                                     Immunogenicity                                                                                                                                                             Safety                                                                   Influence of IS on eff./imm.                                                              LoE           
  ------------------------------ ------ --------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----- ------- ----
  Subesinghe[@R75]               2018   Meta-analysis                     7 studies in RA                                                                                         --                                                                                                                           See column influence of IS                                                                                                                                                 --                                                                       MTX and anti-TNF not associated with reduced immunogenicity                               --    2a      --

  Huang[@R42]                    2017   Meta-analysis                     13 studies in RA (also including pts \<18 years)                                                        --                                                                                                                           Reduced immunogenicity RA compared with HCs for H1N1 strain, not for H3N2 and B\                                                                                           Disease activity not influenced by vaccination\                          GC: No influence\                                                                         --    2a      2a
                                                                                                                                                                                                                                                                                                               Respective SP: 60%, 68%, 61%\                                                                                                                                              AE significantly more frequent in RA (RR 1.77; 95% CI 1.02 to 3.08)      Anti-TNF, RTX: Lower SP rate for H1N1, but not for SC or other strains\                                 
                                                                                                                                                                                                                                                                                                               Lower response with non-adjuvanted vaccine                                                                                                                                                                                                          Other biologics: Lower SP and SC for H1N1                                                               

  Burmester[@R201]               2017   Meta-analysis                     Total in analysis:\                                                                                     Influenza-related AE occurred in 5% of vaccinated pts versus 14% of non-vacc.                                                --                                                                                                                                                                         --                                                                       --                                                                                        2a    --      --
                                                                          171 RA-anti-TNF vacc.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                          382 RA-anti-TNF- non-vacc.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                          All using adalimumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hua[@R77]                      2014   Meta-analysis                     7 studies in RA                                                                                         --                                                                                                                           See column influence of IS                                                                                                                                                 --                                                                       RTX: reduced immunogenicity\                                                              --    2a      --
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Anti-TNF: no influence\                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   For MTX, results differed depending on method of analysis                                               

  Park[@R79]                     2018   RCT                               2 RA groups:156 MTX-cont.160 MTX hold for 2 weeks postvacc.                                             --                                                                                                                           Better response for all strains in patients who hold MTX 2 weeks after vaccination (SP difference H1N1 11% (95% CI 2% to 19%), H3N2 16% (6% to 26%), B 14.7% (5% to 25%)   No SAE\                                                                  --                                                                                        --    1b-2b   2b
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          eight flares (5%) in MTX-cont. and 17 (11%) in MTX-hold group (p=0.07)                                                                                                           

  Park[@R78]                     2017   RCT                               4 RA groups on MTX:54 cont.44 hold 4 weeks pre,49 hold 2 weeks pre/2 weeks posthold 4 weeks postvacc.   --                                                                                                                           Adequate response\                                                                                                                                                         No SAE\                                                                  --                                                                                        --    1b-2b   2b
                                                                                                                                                                                                                                                                                                               Better results in pts who stopped MTX 2 weeks before and after vaccination                                                                                                 Flares tended to be more common in groups 2 and 3 (not significant)                                                                                                              

  Kivitz[@R202]                  2014   RCT                               107 RA-CZP\                                                                                             --                                                                                                                           No difference                                                                                                                                                              No difference in AE:\                                                    Reduced on MTX                                                                            --    1b-2b   4
                                                                          109 RA-PCB                                                                                                                                                                                                                                                                                                                                                                                                      62.3% in PCB versus 63.6% in CZP, mostly mild/moderate\                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Disease activity NR                                                                                                                                                              

  Chen[@R34]                     2018   Cohort (retrospective database)   3748 RA-vacc\                                                                                           Reduced risk of morbidity and mortality in vaccinated pts                                                                    --                                                                                                                                                                         --                                                                       --                                                                                        2b    --      --
                                                                          3748 RA non-vacc                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Jain[@R39]                     2017   Cohort                            51 RA-MTX\                                                                                              --                                                                                                                           No difference                                                                                                                                                              No influence on disease activity\                                        See column immunogenicity                                                                 --    2b      4
                                                                          51 RA-naïve\                                                                                                                                                                                                                                                                                                                                                                                                    No difference in AE                                                                                                                                                              
                                                                          45 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Winthrop[@R84]\                2016   Cohort                            102 RA-TFC\                                                                                             --                                                                                                                           Similar proportions of satisfactory response                                                                                                                               --                                                                       Reduced in TFC/MTX                                                                        --    2b      --
  *Part A*                                                                98 RA-PCB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Winthrop[@R84]\                2016   Cohort                            92 RA-TFC cont. 91 RA-TFC stop                                                                                                                                                                                                       No difference                                                                                                                                                                                                                                       No                                                                                        --    2b      --
  *Part B*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Alten[@R83]                    2016   Cohort                            184 RA ABT+MTX                                                                                          --                                                                                                                           Adequate response                                                                                                                                                          --                                                                       See column immunogenicity                                                                 --    2b      --

  Luque Ramos[@R203]             2016   Cohort (retrospective database)   111482 RA\                                                                                              Trend towards higher hospital admittance rates for pneumonia in areas with lower influenza and pneumococcal vaccine uptake   --                                                                                                                                                                         --                                                                       --                                                                                        5     --      --
                                                                          555410 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kogure[@R74]                   2014   Cohort                            57 RA:\                                                                                                 --                                                                                                                           Seroprotection: H1N1 63%,\                                                                                                                                                 No change in disease activity, no AE.                                    Reduced on biologics                                                                      --    2b      4
                                                                          9 biologics\                                                                                                                                                                                                                         H3N2 81%, influenza B 26%                                                                                                                                                                                                                                                                                                                                   
                                                                          34 MTX\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                          8 TAC\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                          10 GC\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                          14 SASP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Milanetti[@R41]\               2014   Cohort                            30 RA\                                                                                                  --                                                                                                                           No difference                                                                                                                                                              Milder AE in patients.\                                                  No effect of anti-TNF or ABT                                                              --    2b      4
  *Both seasonal and pandemic*                                            13 HCs                                                                                                                                                                                                                                                                                                                                                                                                          No changes in disease activity                                                                                                                                                   

  Kobashigawa[@R36]              2013   Cohort (prospective)              17735 RA in 4 seasons\                                                                                  Vaccination associated with reduced self-reported risk of influenza                                                          --                                                                                                                                                                         --                                                                       No                                                                                        2b    --      --
                                                                          (12.2%--38.7% vacc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Milanovic[@R37]                2013   Cohort                            19 SLE--vacc.\                                                                                          Lower incidence of influenza and bact. Complications among vaccinated pts                                                    Sign. difference in GMT between vacc./unvacc.\                                                                                                                             No changes in disease activity                                           No                                                                                        4     2b      4
                                                                          11 SLE\                                                                                                                                                                                                                              SLE, but not in RA and\                                                                                                                                                                                                                                                                                                                                     
                                                                          15 RA-vacc.\                                                                                                                                                                                                                         SjS.                                                                                                                                                                                                                                                                                                                                                        
                                                                          22 RA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                          13 SjS-vacc.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                          19 SjS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Tsuru[@R81]                    2013   Cohort                            38 TCZ\                                                                                                 --                                                                                                                           No difference                                                                                                                                                              --                                                                       No                                                                                        --    2b      4
                                                                          (28 RA/10 CD)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                          39 RA anti-TNF/DMARD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Mori[@R73]                     2012   Cohort                            62 RA-TCZ\                                                                                                                                                                                                                           Adequate immune response, but lower on MTX                                                                                                                                 No systemic AE\                                                          Reduced on MTX                                                                            --    2b      4
                                                                          65 RA-MTX\                                                                                                                                                                                                                                                                                                                                                                                                      No flares                                                                                                                                                                        
                                                                          49 RA-TCZ +MTX\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                          18 RA-DC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Kogure[@R72]                   2012   Cohort                            RA treated with Japanese Kampo medicine:\                                                               --                                                                                                                           No difference\                                                                                                                                                             No AE\                                                                   No influence of MTX                                                                       --    4       4
                                                                          24 RA+MTX\                                                                                                                                                                                                                           Low response in general                                                                                                                                                    No influence on disease activity                                                                                                                                                 
                                                                          16 RA-DC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Arad[@R38]                     2011   Cohort                            29 RA-RTX (16\<5 mo, 13\>5 mo)\                                                                         --                                                                                                                           Humoral immunity: reduced in RA-RTX\                                                                                                                                       No change in disease activity                                            Humoral immunity:\                                                                        --    2b      4
                                                                          17 RA-DC\                                                                                                                                                                                                                            Similar percentage of influenza-specific IFN-γ producing CD4+ cells in RA groups                                                                                                                                                                    Reduced on RTX\                                                                                         
                                                                          16 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Cellular immunity: No                                                                                   

  Kobie[@R40]                    2011   Cohort                            61 RA-anti-TNF\                                                                                         --                                                                                                                           Reduced in RA-anti-TNF                                                                                                                                                     --                                                                       Reduced on anti-TNF                                                                       --    2b      --
                                                                          70 RA-MTX\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                          33 RA-DC\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                          97 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Rehnberg[@R107]                2010   Cohort                            11 RA 6 mo post-RTX\                                                                                    --                                                                                                                           Lower frequency influenza-specific B cells in peripheral blood in post-RTX group 6 d after vacc.\                                                                          --                                                                       Reduced on RTX                                                                            --    4       --
                                                                          8 RA 6 d pre-RTX\                                                                                                                                                                                                                    Lower humoral response 21 d after vacc. in post-RTX group                                                                                                                                                                                                                                                                                                   
                                                                          10 RA-DC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Salemi[@R71]                   2010   Cohort                            22 RA-anti-TNF\                                                                                         --                                                                                                                           Lower in RA                                                                                                                                                                No SAE\                                                                  --                                                                                        --    2b      4
                                                                          10 HCs                                                                                                                                                                                                                                                                                                                                                                                                          No difference in AE\                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No change in disease activity\                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ANA appearance/increase similar RA and HCs                                                                                                                                       

  Huang[@R47]                    2016   Meta-analysis                     15 studies in SLE (also including pts\<18 years)                                                        --                                                                                                                           Reduced immunogenicity SLE compared with HCs for H1N1 and B, but not for H3N2\                                                                                             Disease activity not influenced by vaccination\                          GC, AZA or IS in general: reduced immunogenicity\                                         --    2a      2a
                                                                                                                                                                                                                                                                                                               Respective SP: 66%, 64%, 60%\                                                                                                                                              No difference in AE between SLE and HCs                                  HCsQ: No difference                                                                                     
                                                                                                                                                                                                                                                                                                               Lower response with non-adjuvanted vaccine                                                                                                                                                                                                                                                                                                                  

  Pugès[@R45]                    2016   Meta-analysis                     17 studies in SLE                                                                                       --                                                                                                                           Immunogenicity depends on viral strains: reduced against A and preserved for B                                                                                             No influence on disease activity                                         --                                                                                        --    2a      2a

  Liao[@R46]                     2016   Meta-analysis                     18 studies in SLE                                                                                       --                                                                                                                           Reduced in SLE for H1N1 and H3N2, but not for B\                                                                                                                           All side effects mild and transient\                                     --                                                                                        --    2a      2a
                                                                                                                                                                                                                                                                                                               Respective SP: 68%, 76%, 66%                                                                                                                                               Similar rate of AE in SLE and HCs\                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          2 severe flares                                                                                                                                                                  

  Chang[@R35]                    2016   Cohort (retrospective database)   1765 SLE-vacc.\                                                                                         Reduction of complications of influenza in vaccinated patients                                                               --                                                                                                                                                                         --                                                                       --                                                                                        2b    --      --
                                                                          8360 SLE non-vacc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Launay[@R204]                  2013   Cohort                            27 SLE                                                                                                                                                                                                                               Percentages of responders at day 30 are 55.5%, 18.5% and 55.5%, for H1N1, H3N2 and influenza B, respectively                                                               Increase in rheumatoid factor levels, after vacc.\                                                                                                                       4       4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No flares.                                                                                                                                                                       

  Vista[@R205]                   2012   Cohort                            101 SLE\                                                                                                --                                                                                                                           --                                                                                                                                                                         Similar proportion new onset anticardiolipin antibodies                  --                                                                                        --    --      4
                                                                          101 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Crowe[@R44]                    2011   Cohort                            72 SLE\                                                                                                 --                                                                                                                           No difference.\                                                                                                                                                            19.4%/26.4% flare 6/12 weeks postvacc.\                                  Reduced on steroids                                                                       --    4       4
                                                                          72 HCs                                                                                                                                                                                                                               More high responses in\                                                                                                                                                    More low responders with flare at 6 weeks.                                                                                                                                       
                                                                                                                                                                                                                                                                                                               African-American subjects.                                                                                                                                                                                                                                                                                                                                  

  Wallin[@R43]                   2009   Cohort                            47 SLE:23 GC8 MTX9 AZA\                                                                                 --                                                                                                                           No difference in seroprotection                                                                                                                                            Overall stable disease                                                   Reduced on steroids                                                                       --    2b      4
                                                                          27 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Jaeger[@R53]                   2017   Cohort                            107 injections influenza vaccine in\                                                                    --                                                                                                                           --                                                                                                                                                                         AE in 7% of injections\                                                  --                                                                                        --    --      4
                                                                          55 CAPS                                                                                                                                                                                                                                                                                                                                                                                                         Fever in 2%\                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No SAE                                                                                                                                                                           

  Caso[@R51]                     2016   Cohort                            25 PsA-vacc.\                                                                                           --                                                                                                                           --                                                                                                                                                                         Higher tender\                                                           --                                                                                        --    --      4
                                                                          25-PsA DC                                                                                                                                                                                                                                                                                                                                                                                                       joint count and\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ESR after 1 month, more episodes mild symptoms in\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PsA- vacc.                                                                                                                                                                       

  Jeffs[@R48]                    2015   Cohort                            24 AAV-vacc.\                                                                                           --                                                                                                                           Adequate, but lower response in AAV                                                                                                                                        No SAE\                                                                  --                                                                                        --    2b      2b
                                                                          67 AAV-non vacc.\                                                                                                                                                                                                                                                                                                                                                                                               Significant increase in local AE following vaccination only in HCs\                                                                                                              
                                                                          53 HCs                                                                                                                                                                                                                                                                                                                                                                                                          No change in disease activity                                                                                                                                                    

  Polachek[@R50]                 2015   Cohort                            63 PsA\                                                                                                 --                                                                                                                           No difference                                                                                                                                                              Increased CRP in patients 4--6\                                          No                                                                                        --    2b      4
                                                                          4 Pso\                                                                                                                                                                                                                                                                                                                                                                                                          weeks postvacc.                                                                                                                                                                  
                                                                          30 HCs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Litinsky[@R49]                 2012   Cohort                            26 SSc\                                                                                                 --                                                                                                                           Increased in SSc for H1N1\                                                                                                                                                 Overall stable disease                                                   Increased on combination iloprost and calcium channel blockers for H1N1 and influenza B   --    2b      4
                                                                          16 HCs                                                                                                                                                                                                                               No difference for H3N2 and influenza B                                                                                                                                                                                                                                                                                                                      

  Kostianovsky[@R52]\            2012   Cohort                            74 systemic vasculitis\                                                                                 --                                                                                                                           No difference                                                                                                                                                              19 flares                                                                No                                                                                        --    4       4
  *Both seasonal and pandemic*                                            32 SSc\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                          29 SLE\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                          23 SjS\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                          28 other AIIRD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The table is structured as follows: First studies in RA, then SLE followed by other autoimmune inflammatory rheumatic diseases (AIIRD). Within this organisation, articles are clustered in study design (meta-analyses, RCT, cohort studies, case series) and presented in order of publication year.

AAV, ANCA-associated vasculitis; ABT, abatacept; ANA, antinuclear antibodies; AZA, azathioprine; bact., bacterial; CAPS, cryopyrin associated periodic syndrome; CD, Castleman's disease; CD, cluster of differentiation; cont., continued; CRP, C reactive protein; CZP, certolizumab pegol; d, days; DC, disease control; DMARD, disease-modifying antirheumatic drug; eff., efficacy; ESR, erythrocyte sedimentation rate; GC, glucocorticoids; GMT, geometrical mean titre; HC, healthy controls; HCQ, hydroxychloroquine; IFN, interferon; imm, immunogenicity; IS, immunosuppressives; LoE, level of evidence; mo., months; MTX, methotrexate; No., number; NR, not reported; PCB, placebo; PsA, psoriatic arthritis; Pso, psoriasis; pts, patients; RA, rheumatoid arthritis; RCT, randomised controlled trial; ref., reference; RR, relative risk; RTX, rituximab; (S)AE, (serious) adverse event(s); saf., safety; SASP, salazosulfapyridine; SC, seroconversion; sign, significant; SjS, Sjögren's syndrome; SLE, systemic lupus erythematosus; SP, seroprotection; SSc, systemic sclerosis; TAC, tacrolimus; TCZ, tocilizumab; TFC, tofacitinib; TNF, tumor necrosis factor; vacc., vaccinated; yrs, years.

###### 

Efficacy, immunogenicity and safety of monovalent (H1N1) pandemic influenza vaccination in patients with AIIRD (October 2009--August 2018)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author +ref.                          Year   Study design   No. cases                   Efficacy   Immunogenicity                                                                                             Safety                                                                                                                 Influence of IS on eff./ imm.                               LoE        
  ------------------------------------------- ------ -------------- --------------------------- ---------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ----- ---- ----
  Milanetti[@R41]\                            2014   Cohort         30 RA\                      --         No difference                                                                                              More mild AE in patients                                                                                               No effect of anti-TNF or ABA                                --    2b   4
  *Both seasonal and pandemic, adj. (MF59*)                         13 HC                                                                                                                                                                                                                                                                                                                                           

  Kapetanovic[@R62]\                          2014   Cohort         50 RA-MTX\                  --         Reduced in RA-RTX\                                                                                         One pneumonia\                                                                                                         Reduced on RTX and ABA (only five pts)                      --    2b   4
  *Adj. (AS03*)                                                     38 RA-anti-TNF\                        Increased in SpA-anti-TNF\                                                                                 8.2% of patients reported that vaccination influenced their rheumatic disease                                                                                                                 
                                                                    53 RA-anti-TNF+MTX\                    Increased after two doses, except for RA-MTX and RA-\                                                                                                                                                                                                                                                    
                                                                    5 RA-ABA-\                             RTX                                                                                                                                                                                                                                                                                                      
                                                                    10 RA-RTX\                                                                                                                                                                                                                                                                                                                                      
                                                                    2 RA TCZ\                                                                                                                                                                                                                                                                                                                                       
                                                                    41 SpA-anti-TNF\                                                                                                                                                                                                                                                                                                                                
                                                                    51 SpA-anti-TNF+MTX\                                                                                                                                                                                                                                                                                                                            
                                                                    Two doses in 58%                                                                                                                                                                                                                                                                                                                                

  Ribeiro[@R82]\                              2013   Cohort         11 RA-ABA\                  --         Reduced in RA-ABA                                                                                          No difference AE.                                                                                                      Reduced on ABA                                              --    2b   4
  *Non-adj*.\                                                       33 RA-MTX DC\                                                                                                                                                                                                                                                                                                                                   
  *Subanalysis of*[@R58]                                            55 HC                                                                                                                                                                                                                                                                                                                                           

  Adler[@R59]\                                2012   Cohort         47 RA\                      --         Reduced in patients\                                                                                       No difference in AE. Increase disease activity in 32 patients                                                          Reduced on ABA, RTX (n=8) and MTX\                          --    2b   4
  *AS03 adjuvanted*                                                 59 SpA\                                (but not in SpA and CTD)                                                                                                                                                                                                          2 responders in RTX group: 1 and 3 mo after RTX                        
                                                                    15 vasculitis\                                                                                                                                                                                                                                                                                                                                  
                                                                    28 CTD\                                                                                                                                                                                                                                                                                                                                         
                                                                    40 HC                                                                                                                                                                                                                                                                                                                                           

  França[@R60]\                               2012   Cohort         41 RA-anti-TNF\             --         Reduced in SpA-anti-TNF but not for etanercept                                                             More mild systemic AE in patients on anti-\                                                                            Reduced on MTX (RA). Reduced on anti-TNF (SpA)\             --    2b   4
  *Non-adj*.                                                        79 SpA-anti-TNF\                                                                                                                                  TNF                                                                                                                    (except etanercept)                                                    
                                                                    41 RA-DC\                                                                                                                                                                                                                                                                                                                                       
                                                                    75 SpA-DC\                                                                                                                                                                                                                                                                                                                                      
                                                                    117 HC                                                                                                                                                                                                                                                                                                                                          

  Iwamoto[@R61]\                              2012   Cohort         89 RA\                      --         Reduced (non-significant) in\                                                                              1 facial palsy                                                                                                         Lower (non-significant) on biologics                        --    2b   5
  *Mostly non-adj*.                                                 14 HC                                  RA\                                                                                                                                                                                                                                                                                                      
                                                                                                           Seroprotection 55.1%                                                                                                                                                                                                                                                                                     

  Saad[@R54]\                                 2011   Cohort         1668 AIIRD\*\               --         Reduced in AIIRD versus HC\                                                                                Overall stable disease                                                                                                 No                                                          --    2b   4
  *Non-adj*.                                                        234 HC                                 Reduced in SLE and RA                                                                                                                                                                                                                                                                                    

  Gabay[@R55]\                                2011   Cohort         82 RA\                      --         Reduced in patients\                                                                                       Overall stable disease                                                                                                 Reduced on DMARDs and within 3 mo. after B cell depletion   --    2b   4
  *Adj. (AS03*)                                                     45 SpA\                                No difference after two doses in patients (seroprotection after 1 and 2 doses 75% and 85%, respectively)                                                                                                                                                                                                 
                                                                    46 other AIIRD\                                                                                                                                                                                                                                                                                                                                 
                                                                    138 HC                                                                                                                                                                                                                                                                                                                                          

  Miraglia[@R56]\                             2011   Cohort         1152 Immunocompromised†:\   --         Seroprotection in 61.5% of\                                                                                Mild systemic\                                                                                                         --                                                          --    2b   4
  *Non-adj*.                                                        260 RA\                                patients with RA and in 85.5% of patients with JIA                                                         AE in more than 20% of RA and JIA                                                                                                                                                             
                                                                    83 JIA                                                                                                                                                                                                                                                                                                                                          

  Elkayam[@R57]\                              2011   Cohort         41 RA\                      --         Reduced in patients with RA/PsA\                                                                           Overall stable disease                                                                                                 Reduced on leflunomide and infliximab                       --    2b   4
  *Adj. (MF59*)                                                     21 SLE\                                Seroprotection in 60%--76% of patients                                                                                                                                                                                                                                                                   
                                                                    17 PsA\                                                                                                                                                                                                                                                                                                                                         
                                                                    15 AS\                                                                                                                                                                                                                                                                                                                                          
                                                                    25 HC                                                                                                                                                                                                                                                                                                                                           

  Ribeiro[@R58]\                              2011   Cohort         340 RA\                     --         Reduced in RA\                                                                                             More local AE in HC. More mild systemic AE in RA                                                                       Reduced on MTX                                              --    2b   2b
  *Non-adj*.                                                        234 HC                                 No influence of disease activity                                                                                                                                                                                                                                                                         

  Müller[@R206]\                              2013   Case series    16 RA+SjS                   --         SC in B cell depleted: 22%, non-depleted: 57%                                                              More influenza-like symptoms in B cell depleted patients                                                               Low response with RTX                                       --    4    5
  *Adj. (AS03*)                                                                                                                                                                                                                                                                                                                                                                                                     

  Borba[@R64]\                                2012   Cohort         555 SLE\                    --         Reduced in SLE with therapy (except for antimalarials)\                                                    Overall stable disease                                                                                                 Reduced for steroids and IS\                                --    2b   2b
  *Non-adj*.                                                        170 HC                                 No difference in HC and SLE without therapy                                                                                                                                                                                       Restored when using concomitant antimalarials                          

  Kostianovsky[@R52]\                         2012   Cohort         74 systemic vasculitis\     --         No difference                                                                                              19 flares                                                                                                              No                                                          --    4    4
  *Both seasonal and pandemic, non-adj*.                            32 SSc\                                                                                                                                                                                                                                                                                                                                         
                                                                    29 SLE\                                                                                                                                                                                                                                                                                                                                         
                                                                    23 SjS\                                                                                                                                                                                                                                                                                                                                         
                                                                    28 other AIIRD                                                                                                                                                                                                                                                                                                                                  

  Lu[@R63]\                                   2011   Cohort         21 SLE\                     --         No difference                                                                                              Changes in autoantibody levels\                                                                                        No                                                          --    2b   4
  *Non-adj*.                                                        15 HC                                                                                                                                             Overall stable clinical disease activity\                                                                                                                                                     
                                                                                                                                                                                                                      one flare                                                                                                                                                                                     

  Urowitz[@R207]\                             2011   Cohort         103 SLE:\                   --         --                                                                                                         No difference\                                                                                                         --                                                          --    --   2b
  *Both adj. and non-adj*.                                          51 adj.\                                                                                                                                          Overall stable disease                                                                                                                                                                        
                                                                    52 non-adj.                                                                                                                                                                                                                                                                                                                                     

  Mathian[@R69]\                              2011   Cohort         111 SLE                     --         Increased after booster vaccination (seroprotection after 1 and 2 doses 67% and 80%, respectively)         No severe AE\                                                                                                          Reduced on IS                                               --    2b   4
  *Non-adj*.                                                                                                                                                                                                          Overall stable disease                                                                                                                                                                        

  Brauner[@R67]                               2017   Cohort         14 SjS\                                Higher levels of influenza-specific IgG in patients, and higher avidity                                    Antibody titres to non-influenza (incl autoantigens Ro/SSA and La/SSB) antigen increased in patients, but not in HC.   --                                                          --    4    4
                                                                    18 HC                                                                                                                                                                                                                                                                                                                                           

  Sampaio-Barros[@R68]                        2017   Cohort         92 SSc\                     --         Higher GMT SSc\                                                                                            No difference in AE\                                                                                                   No                                                          --    2b   4
                                                                    92 HC                                  Comparable SP and SC                                                                                       No SAE                                                                                                                                                                                        

  De Medeiros[@R208]\                         2014   Cohort         45 PAPS\                    --         --                                                                                                         No change in overall frequencies of autoantibodies                                                                     --                                                          --    --   2b
  *Non-adj*.                                                        33 HC                                                                                                                                                                                                                                                                                                                                           

  Miossi[@R66]\                               2013   Cohort         69 MCTD\                    --         No difference                                                                                              Overall stable disease                                                                                                 No                                                          --    2b   4
  *Non-adj*.                                                        69 HC                                                                                                                                                                                                                                                                                                                                           

  Shinjo[@R65]\                               2012   Cohort         37 DM +21 PM\               --         No difference                                                                                              No difference\                                                                                                         No                                                          --    2b   4
  *Non-adj*.                                                        116 HC                                                                                                                                            Overall stable disease                                                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The table is structured as follows: First studies in RA, then systemic lupus erythematosus (SLE) followed by other autoimmune inflammatory rheumatic diseases (AIIRD). Within this organisation, presented in order of publication year.

\*Group consisted of patients with SLE (n=572), RA (n=343), psoriatic arthritis (n=101), ankylosing spondylitis (n=152), Behçet's disease (n=85), dermatomyositis (n=45), systemic sclerosis (n=127), mixed connective tissue disease (n=69), primary antiphospholipid syndrome (n=54), primary Sjögren's syndrome (n=36), Takayasu's arteritis (n=30), polymyositis (n=28), granulomatosis with polyangiitis (n=26).

†Group consisted of patients with cancer (n=319), RA (n=260), HIV infection (n=256), kidney transplant recipients (n=85), juvenile idiopathic arthritis (n=83) and elderly persons (n=149).

ABA, abatacept; adj., adjuvanted; AS, ankylosing spondylitis; AS, adjuvant system; DC, disease control; DM, dermatomyositis; DMARD, disease-modifying antirheumatic drug; eff., efficacy; GMT, geometrical mean titre; HC, healthy controls; imm, immunogenicity; IS, immunosuppressives; JIA, juvenile idiopathic arthritis; LoE, level of evidence; (M)CTD, (mixed) connective tissue disease; mo., months; MTX, methotrexate; No., number; PAPS, primary antiphospholipid syndrome; PM, polymyositis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; ref., reference; RTX, rituximab; (S)AE, (serious) adverse event(s); saf., safety; SC, seroconversion; SjS, Sjögren's syndrome; SP, seroprotection; SpA, spondyloarthropathy; SSc, systemic sclerosis; TCZ, tocilizumab; TNF, tumor necrosis factor.

Five studies addressed the efficacy of influenza vaccination. Retrospective database analysis studies reported a reduced all-cause mortality rate and risk of hospitalisation for influenza-related complications in patients with RA[@R34] and SLE[@R35] who received trivalent seasonal subunit influenza vaccine. A prospective Japanese study following a total of 17 735 patients with RA during four influenza seasons, found that trivalent subunit influenza vaccination was associated with a lower self-reported rate of influenza infections (RR 0.83, 95% CI 0.71 to 0.95).[@R36] These findings are supported by two prospective cohort studies.[@R6]

Most studies on influenza vaccination in patients with AIIRD, however, address immunogenicity, mainly by assessing the development of a protective level of antibodies (titre value ≥40, as measured by the haemagglutination inhibition assay). For RA, most of these studies report similar responses in patients and HCs.[@R7] A meta-analysis including a total of 886 patients with RA and 685 controls concluded that 60%, 68% and 61% of patients with RA reached seroprotective antibody levels following influenza vaccination for the H1N1, H3N2 and B strain, respectively. Only for the H1N1 influenza strain, the strain for which most data were available, responses were significantly lower in patients than in HCs.[@R42]

For SLE most studies report similar, adequate immune responses using trivalent seasonal subunit influenza vaccine,[@R17] although modestly lower responses compared with HCs were also reported.[@R21] Two meta-analyses reported an adequate but lower response against influenza A strains (H1N1 and H3N2) but not against influenza B in patients with SLE as compared with HCs,[@R45] while another meta-analysis reported a reduced immunogenicity in SLE for H1N1 and B strains, but not for H3N2.[@R47] Reported pooled seroprotection rates in patients with SLE are 66%--68%, 64%--76% and 60%--66% against H1N1, H3N2 and B strains, respectively.[@R46]

Likewise, in other AIIRD, including patients with spondyloarthropathies, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis and primary systemic sclerosis (pSS), adequate serological responses to influenza vaccination were found.[@R30]

Regarding the pandemic monovalent subunit influenza vaccine, most larger studies report reduced immunogenicity in patients with AIIRD (mostly RA and SLE), although protective antibody levels were reached in the majority of patients.[@R41] A second booster dose of vaccine, given 3--4 weeks after the first, improved immunogenicity, resulting in seroprotection levels comparable to those of HCs.[@R55] This phenomenon has also been shown in patients with SLE who received seasonal influenza vaccine for the first time.[@R70] High disease activity levels did not preclude reaching seroprotection in a study that included 340 patients with RA, of which 14.5% had a DAS 28 (Disease Activity Score in 28 joints) value above 5.1.[@R58]

Influenza vaccination did not influence activity of the underlying AIIRD in patients with RA,[@R7] SLE,[@R6] ANCA-associated vasculitis[@R30] or systemic sclerosis.[@R32] Adverse events of influenza vaccination in patients with AIIRD were comparable to those in HCs in most studies,[@R7] including a meta-analysis in patients with SLE,[@R46] In contrast, a meta-analysis including 13 studies in patients with RA concluded that local, mild adverse events occurred significantly more frequently in patients with RA.[@R42]

### Influence of immunomodulating agents {#s3-1-2}

The influence of immunomodulating agents on influenza vaccine efficacy and immunogenicity is summarised in [table 6](#T6){ref-type="table"}. No influence of methotrexate (MTX) on influenza immunogenicity was found in most studies[@R39] including one meta-analysis in patients with RA.[@R75] In some, a modest reduction in immunogenicity was observed.[@R58] In another meta-analysis, results on the influence of MTX differed depending on whether response rates per influenza strain, or for at least two of the three strains, were analysed. In case of the latter approach, the negative impact of MTX was significant.[@R77] Interestingly, temporary discontinuation of MTX was shown to significantly improve immunogenicity of seasonal influenza vaccination in patients with RA in two studies by Park *et al*.[@R78] Discontinuation of MTX for 2 weeks after influenza vaccination led to a 11%--16% (depending on influenza strain) higher seroprotection rate compared with patients with RA who continued the use of MTX. Flare rates tended to be higher in patients with RA who temporarily halted MTX use, but the increase in disease activity was transient.[@R78]

###### 

Influence of disease-modifying antirheumatic drugs on influenza and pneumococcal vaccine efficacy and immunogenicity

  ---------------------------------------------------------------------------------------------------------------------------------------------
                                Efficacy   Immunogenicity                                                             LoE Immunogenicity   
  ----------------------------- ---------- -------------------------------------------------------------------------- -------------------- ----
  MTX                           No data    Adequate for influenza/reduced for pneumococcal                            2a                   2b

  Other cs-DMARD                No data    Only for HCQ\                                                              4                    4
                                           Adequate                                                                                        

  Anti-TNFα                     No data    Adequate                                                                   2a                   2b

  B cell depletion              No data    Reduced                                                                    2a                   2b

  Belimumab                     No data    Pneumococcal: preserved                                                    --                   2b

  Tocilizumab                   No data    Preserved                                                                  2b                   2b

  Abatacept                     No data    Controversial\                                                             4                    4
                                           Probably mildly reduced                                                                         

  Tofacitinib                   No data    Adequate for influenza, reduced for pneumococcal                           2b                   2b

  Glucocorticoids (±other IS)   No data    Adequate for influenza, mildly reduced in high doses GC for pneumococcal   4                    2b
  ---------------------------------------------------------------------------------------------------------------------------------------------

cs-DMARD, conventional synthetic disease-modifying antirheumatic drugs; GC, glucocorticoids; HCQ, hydroxychloroquine;IS, immunosuppressives; LoE, level of evidence; MTX, methotrexate; TNF, tumour necrosis factor.

Hydroxychloroquine does not influence the development of an adequate immune response to influenza vaccination.[@R47] The same holds true for the use of TNFα-blocking agents in the majority of studies,[@R11] including two meta-analyses in RA.[@R75] Another meta-analysis reported a lower seroprotection, but not seroconversion rate in patients with RA on anti-TNF α, only for the H1N1 influenza strain.[@R42] Four studies did report a modestly reduced response to influenza vaccination in patients using anti-TNFα.[@R10]

B cell depleting therapy has been associated with hampered antibody responses following influenza vaccination in multiple studies. A negative influence of B cell depleting therapy was observed in two meta-analyses that pooled data from cohort studies. Patient numbers in analyses were low however, and CIs were wide.[@R42] The interval between administration of rituximab and vaccination differed between studies. A study that included both patients with RA vaccinated 4--8 weeks (n=11) and 6--10 months after (n=12) the administration of rituximab demonstrated no response to influenza vaccination in the first, early group and a modestly restored response in the late group.[@R14] The use of rituximab did not seem to affect cell-mediated immune responses to influenza vaccination in a study with a limited number of patients.[@R38]

Two studies demonstrated that patients with RA treated with tocilizumab, an IL-6 receptor blocking agent, were able to mount a satisfactory antibody response following influenza vaccination.[@R73]

Controversial data have been published on the effect of abatacept on influenza vaccine immunogenicity. Most of the studies were small in patient numbers, but they reported a substantial negative effect.[@R59] One relatively large but uncontrolled study, including 184 patients with RA, reported an adequate humoral response to influenza vaccination.[@R83]

Only one study investigated the influence of tofacitinib on influenza vaccine immunogenicity in AIIRD. Tocafitinib alone did not seem to affect the immune response to the vaccine, but a combination of tofacitinib and methotrexate was associated with a lower response.[@R84]

The effect of glucocorticoids on the immune response to influenza vaccine has mainly been studied in combination with other immunosuppressive agents. The antibody response is generally adequate in patients who were on glucocorticoids at the time of influenza vaccination,[@R21] although some studies did find a mildly reduced response.[@R17]

### Summary and clinical implications {#s3-1-3}

Seasonal trivalent influenza vaccination is associated with a reduced incidence of bacterial complications, hospital admissions and mortality in patients with RA and SLE. It has also been proven to be immunogenic in the majority of studies in patients with AIIRD, even when treated with immunosuppressive agents, with the exclusion of B cell depletion. Although studies that are sufficiently powered with regard to safety are lacking, in the majority of studies disease activity remained stable and only mild adverse events were reported, comparable with HCs. Therefore, the updated EULAR recommendation on influenza states that influenza vaccination should be strongly considered for the majority of patients with AIIRD.[@R3]

Pneumococcal vaccination {#s3-2}
------------------------

### Efficacy⁠---immunogenicity⁠---safety {#s3-2-1}

To date, 91 pneumococcal serotypes have been identified, 30 of them being responsible for up to 90% of all infections.[@R85] Although the pneumococcal polysaccharide vaccine that includes 23 serotypes (PPSV23) was found to prevent invasive pneumococcal infections in the general population, it did not generate immunity in children younger than 2 years of age and had a limited efficacy in reducing non-bacteraemic pneumonia.[@R86] Therefore, in 2000 a pneumococcal conjugate vaccine comprising seven antigens (PCV7) was developed and expanded to 13 serotypes (PCV13) which was licensed in 2010 based on immunogenicity outcome studies.[@R87] In 2015, a randomised controlled study performed in the older healthy population demonstrated the capacity of PCV13 to prevent vaccine-type pneumococcal, bacteraemic and non-bacteraemic community-acquired pneumonia as well as vaccine-type invasive disease.[@R89]

Up to the previous recommendations, 15 studies addressed the issue of immunogenicity and safety of PCV13 and PPSV23 in patients with AIIRD: 7 studies in RA,[@R8] 8 in SLE,[@R95] 2 in patients with spondyloarthropathy (SpA)[@R91] and 1 in pSS.[@R104] Adequate as well as reduced immunogenic responses compared with controls were reported in these studies. Treatment with rituximab, TNFα blockers and MTX seemed to impair the humoral response to the pneumococcal vaccine.[@R16]

From the previous recommendations and up to August 2018, 34 studies[@R53] and two meta-analyses[@R45] have been published on the efficacy, immunogenicity and safety of PPSV23 and the conjugated vaccines PCV7 and PCV13, including evaluation of a combined strategy ([tables 7 and 8](#T7 T8){ref-type="table"}).[@R106]

###### 

Efficacy, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with AIIRD (October 2009--August 2018)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author +ref.    Year   Study design             No. cases                                              No.\   Efficacy                                        Immunogenicity                                              Safety                     LoE             
                                                                                                               ST                                                                                                                                                            
  --------------------- ------ ------------------------ ------------------------------------------------------ ------ ----------------------------------------------- ----------------------------------------------------------- -------------------------- ------- ------- ----
  Izumi[@R120]          2017   RCT                      464 RA--vaccinated\                                    NA     Similar efficacy in vaccinated versus placebo   --                                                          No safety issue            1b-2b   --      --
                                                        436 RA--placebo                                                                                                                                                                                                      

  Kivitz[@R76]          2014   RCT                      110 RA-Certolizumab\                                   6      --                                              No difference between certolizumab and placebo              --                         --      1b-2b   --
                                                        (68%+MTX)\                                                                                                                                                                                                           
                                                        114 RA-Placebo\                                                                                                                                                                                                      
                                                        (68%+MTX)                                                                                                                                                                                                            

  Hesselstrand[@R131]   2018   Cohort                   44 SSc:31 PPSV2313 PCV13\                              2      --                                              Lower response in patients treated with DMARDs              No safety issue            --      2b      4
                                                        49 HC                                                                                                                                                                                                                

  Jaeger[@R53]          2017   Cohort                   16 patients with CAPS                                  NA     --                                              --                                                          Significant side effects   --      4       --

  Chatham[@R125]        2017   Cohort                   34 SLE PPSV23 4 weeks before, and\                     23     --                                              Adequate response, not affected by belimumab                No safety issue            --      2b      4
                                                        45 SLE 24 weeks after belimumab                                                                                                                                                                                      

  Broyde[@R130]         2016   Cohort (retrospective)   88 RA and SpA vaccinated\                              NA     --                                              Preserved immunogenicity after 7 years                      --                         --      2b      --
                                                        42 RA and SpA non-vaccinated                                                                                                                                                                                         

  Winthrop[@R84]\       2016   Cohort                   102 RA-Tofacitinib\                                    12     --                                              Reduced response in tofacitinib-treated patients            --                         --      2b      --
  *Part A*                                              98 RA-Placebo                                                                                                                                                                                                        

  Winthrop[@R84]\       2016   Cohort                   92 RA-Cont Tofacitinib\                                12     --                                              No difference between groups                                --                         --      2b      --
  *Part B*                                              91 RA-Stop Tofacitinib                                                                                                                                                                                               

  Alten[@R83]           2016   Cohort                   125 RA ABA+MTX                                         5      --                                              Adequate response                                           No safety issue                    2b      4

  Rezende[@R116]        2016   Cohort                   54 SLE                                                 7      --                                              Poor immunogenicity                                         --                                 2b      --

  Migita[@R109]         2015   Cohort                   35 RA-DMARDs\                                          2      --                                              Reduced response in abatacept-treated patients              No safety issue                    2b      4
                                                        55 RA-MTX\                                                                                                                                                                                                           
                                                        21 RA-ABA +MTX                                                                                                                                                                                                       

  Migita[@R124]         2015   Cohort                   35 RA-DMARDs\                                          2      --                                              Reduced response in golimumab-treated patients              No safety issue                    2b      4
                                                        55 RA-MTX\                                                                                                                                                                                                           
                                                        24 RA-Golimumab +MTX                                                                                                                                                                                                 

  Migita[@R119]         2015   Cohort                   35 RA-DMARDs\                                          2      --                                              Higher response in tacrolimus-treated patients              No safety issue                    2b      4
                                                        55 RA-MTX\                                                                                                                                                                                                           
                                                        29 RA-Tacrolimus\                                                                                                                                                                                                    
                                                        14 RA-Tacrolimus +MTX                                                                                                                                                                                                

  Bingham[@R112]        2015   Cohort                   27 RA-MTX\                                             12     --                                              Similar response in patients treated with MTX or MTX +TCZ   No safety issue                    2b      4
                                                        54 RA-MTX +TCZ                                                                                                                                                                                                       

  Fischer[@R115]        2015   Cohort                   57 vaccinated/122 non-vaccinated RA, SpA, vasc., CTD   NR     --                                              Adequate response                                           --                                 4       --

  Tsuru[@R81]           2014   Cohort                   21 RA-TCZ                                              12     --                                              All TCZ-treated patients responded                          --                                 2b      --

  Mori[@R113]           2013   Cohort                   62 RA-MTX\                                             2      --                                              Better response in patients treated with TCZ                No safety issue                    2b      4
                                                        54 RA-MTX+TCZ\                                                                                                                                                                                                       
                                                        50 RA-TCZ\                                                                                                                                                                                                           
                                                        24 RA-DMARDs                                                                                                                                                                                                         

  Coulson[@R121]        2011   Cohort (retrospective)   124 RA vaccinated\                                     NA     Reduced rate of pneumonia in vaccinated         Preserved immunogenicity after 7 years                      --                         4       2b      
                                                        28 RA non-vaccinated                                                                                                                                                                                                 

  Rehnberg[@R107]       2010   Cohort                   11 RA-RTX 36 weeks\                                    NR     --                                              Reduced in patients treated with RTX                        --                                 4       --
                                                        8 RA-Pre-RTX 1 week\                                                                                                                                                                                                 
                                                        10 RA-DC                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABA, abatacept; CAPS, cryopyrin-associated periodic syndrome; cont., continued; CTD, connective tissue disease; DC, disease control; DMARD, disease-modifying antirheumatic drug; eff., efficacy; HC, healthy controls; imm., immunogenicity; LoE, level of evidence; MTX, methotrexate; No., number; NR, not reported; PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine; RA, rheumatoid arthritis; RCT, randomised controlled trial; Ref., reference; RTX, rituximab; saf., safety; SLE, systemic lupus erythematosus; SpA, spondyloarthropathy; SSc, systemic sclerosis; ST, serotypes; TCZ, tocilizumab; vasc., vasculitis.

###### 

Immunogenicity and safety of 7-valent and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13), including prime boosting with 23-valent pneumococcal polysaccharide vaccine (PPSV23), in patients with AIIRD (October 2009--August 2018)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author +ref.                            Year   Study design   No. cases                         Strategy              No. ST   Immunogenicity                                                                          Safety            LoE   
  --------------------------------------------- ------ -------------- --------------------------------- --------------------- -------- --------------------------------------------------------------------------------------- ----------------- ----- ----
  PCV7                                                                                                                                                                                                                                                 

   Grabar[@R128]                                2017   RCT            46 SLE:\                          NA                    7        Adequate immunogenicity\                                                                No safety issue   1b    4
                                                                      27 placebo +PPSV23\                                              No differences between groups                                                                                   
                                                                      19 PCV7 +PPSV23                                                                                                                                                                  

   David Morgan[@R105]                          2016   Cohort         92 AAV                            NA                    7        Preserved immunogenicity in patients on remission                                       --                2b    --

   Nagel[@R123]                                 2015   Cohort         248 RA\                           NA                    2        Good correlation between levels of immunogenicity and incidence of pneumonia            --                2b    --
                                                                      249 SpA                                                                                                                                                                          

   Kapetanovic[@R108]                           2013   Cohort         173 RA\                           NA                    2        Reduced response in patients treated with ABA and RTX                                   No safety issue   2b    4
                                                                      (TCZ, RTX, ABA, MTX)\                                                                                                                                                            
                                                                      86 SpA controls                                                                                                                                                                  

   Kapetanovic[@R127]                           2013   Cohort         163 RA\                           NA                    2        Reduced immunogenicity after 1.5 y                                                      --                2b    --
                                                                      139 SpA                                                                                                                                                                          

   Kapetanovic[@R110]                           2011   Cohort         253 RA\                           NA                    2        Reduced response in pts treated with MTX                                                No safety issue   2b    4
                                                                      252 SpA\                                                                                                                                                                         
                                                                      (MTX, anti-TNF)                                                                                                                                                                  

   Kapetanovic[@R111]                           2011   Cohort         201 RA (PCV7)\                    NA                    2        Similar immunogenicity for PCV7 and PPSV23                                              No safety issue   2b    4
                                                                      201 RA (PPSV23)                                                                                                                                                                  

  PCV13, including prime boosting with PPSV23                                                                                                                                                                                                          

   Nguyen[@R106]                                2017   RCT            98 RA\                            PCV 13+PPSV23\        12       Adequate and similar response in the three arms                                         No safety issue   2b    4
                                                                      63 bDMARD\                        PCV13 +PPSV23\                                                                                                                                 
                                                                      35 csDMARD-DC                     PCV13 +PCV13+PPSV23                                                                                                                            

   Bahuaud[@R133]                               2018   Cohort         23 RA                             PCV13 +PPSV23         10       Adequate short-term response\                                                           --                2b    --
                                                                                                                                       Functional antibodies decreased after 2 years                                                                   

   Kapetanovic[@R118]                           2017   Cohort         10 RA-MTX\                        PCV13                 2        Reduced response in MTX-treated patients                                                --                4     --
                                                                      10 RA-DC                                                                                                                                                                         

   Nived[@R117]                                 2017   Cohort         49 vasculitis\                    PCV13                 2        Adequate response, similar in both groups                                               No safety issue   2b    4
                                                                      49 HC                                                                                                                                                                            

   Nagel[@R114]                                 2017   Cohort         47 SLE\                           PCV13                 12       Decreased response in IS-treated patients with SLE, preserved under HCQ and belimumab   No safety issue   2b    4
                                                                      21 HC                                                                                                                                                                            

   Rakoczi[@R129]                               2016   Cohort         22 RA\                            PCV13                 NR       Adequate immunogenicity, but lower in RA                                                No safety issue   2b    4
                                                                      24 OA                                                                                                                                                                            

   Groh[@R132]                                  2017   Case series    19 AAV9 induction10 maintenance   PCV13/PCV 7±PPSV23    7        Decreased response on induction, preserved on maintenance therapy                       --                4     --
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAV, ANCA-associated vasculitis; ABA, abatacept; ANCA, antineutrophil cytoplasmic antibodies; bDMARD, biological disease-modifying antirheumatic drug; (cs)DMARD, (conventional synthetic) DMARD; DC, disease control; HC, healthy controls; HCQ, hydroxychloroquine; imm., immunogenicity; IS, immunosuppressives; LoE, level of evidence; MTX, methotrexate; No., number; NR, not reported; OA, osteoarthritis; pts, patients; RA, rheumatoid arthritis; RCT, randomised controlled trial; ref., reference; RTX, rituximab; saf., safety; SLE, systemic lupus erythematosus; SpA, spondyloarthropathy; ST, serotypes; TCZ, tocilizumab; TNF, tumor necrosis factor; y, years.

Regarding efficacy of pneumococcal vaccination in AIIRD, a randomised double-blind trial on the clinical efficacy of PPSV23 in preventing pneumonia in patients with RA did not demonstrate an increased efficacy of the vaccine over placebo, emphasising the need for a more efficacious vaccine.[@R120] In contrast, a retrospective study on the long-term effect of PPSV23 in 180 patients with RA treated with MTX showed a relative risk of 9.7 to develop pneumonia among non-vaccinated patients.[@R121] Vaccination with PCV7 tended to reduce the risk of pneumococcal infections in patients with RA and SpA.[@R122] In this cohort, a direct correlation was shown between the postvaccination levels of antipneumococcal antibodies and the risk of pneumococcal infections: more robust antibody responses after vaccination with PCV7 were associated with lower risk of serious pneumococcal infections.[@R123] The humoral immunogenicity and safety of PPSV23 were demonstrated in RA,[@R76] SLE,[@R116] and, to a limited extent, in SpA and other rheumatic diseases.[@R115] The long-term immunogenicity of PPSV23 was evaluated in two studies in patients with RA, treated with MTX[@R121] and biologics.[@R130] Both have shown a long-term duration of protective antibodies, up to 7 years.

Humoral immunogenicity of PCV7 is similar to that of PPSV23,[@R111] but was shown to decrease after 1.5 years.[@R127] A randomised controlled study in patients with SLE aiming at evaluating the immunogenicity of the combination of PCV7 and PPSV23 in comparison with PPSV23, showed an adequate and similar response in the two groups.[@R128] The immunogenicity of PCV7 is preserved in patients with ANCA-associated vasculitis on remission.[@R105]

The immunogenicity of PCV13 has been evaluated in small groups of patients with RA,[@R118] SLE[@R114] and pSS.[@R131] It induced an adequate humoral response.

Three studies evaluated the prime-boost strategy. In SLE, the combination of PCV7 and PPSV23 was not more immunogenic than PPSV23 alone.[@R128] Another randomised controlled study evaluated the serological response to PCV13 followed by PPSV23 after 16--24 weeks in patients with RA, with one of the arms including two doses of PCV13. This study demonstrated an adequate response in patients with RA (87% and 94% on biological disease-modifying antirheumatic drugs (DMARDs) and conventional synthetic DMARDs, respectively), without additional effect of two PCV13 injections.[@R106] An additional study has questioned the long-term effect of the prime boosting strategy using PCV13 and PPSV23, showing reduced levels of functional antibodies 2 years after vaccination.[@R133]

No safety issues following pneumococcal vaccination in most of the AIIRDs were reported, independent of vaccine type (see [tables 7 and 8](#T7 T8){ref-type="table"}). In contrast, data from the b-CONFIDENT Study in patients with cryopyrin associated periodic syndrome (CAPS) and from a case series of seven patients with CAPS showed that PPSV23 might induce severe local reactions and systemic reactions in these patients (fever, headache, meningismus, nausea), necessitating hospitalisation.[@R126] All symptoms resolved within a period of 3--17 days.

### Influence of immunomodulating agents {#s3-2-2}

Humoral immunogenicity of PPSV23 has been shown to be reduced by MTX,[@R119] abatacept,[@R109] golimumab,[@R124] tofacitinib[@R84] and rituximab,[@R90] but not to be affected by certolizumab[@R76] and belimumab.[@R125] Immunogenicity following PCV7 vaccination is reduced by the use of MTX,[@R110] abatacept and rituximab,[@R108] but not by TNFα blockers.[@R110] Additionally, the humoral response of PCV13 is reduced under MTX.[@R118] A randomised controlled study in patients with RA that evaluated the serological response to PCV13 followed by PPSV23 after 16--24 weeks, showed a significantly decreased response in patients treated with rituximab. The prime-boost strategy with PCV13 did not improve the response[@R106] (see [table 6](#T6){ref-type="table"} for summary).

### Summary and clinical implications {#s3-2-3}

Stepwise pneumococcal vaccination, according to the prime-boost strategy (PCV13 followed by PPSV23, with an interval of at least 8 weeks between the two vaccinations) is currently recommended by the Centers for Disease Control and Prevention (CDC) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) for young children, adults above 65 years of age and patients at risk for pneumococcal disease.[@R135] This is mainly based on expert opinion, although studies conducted in the general population[@R136] and in patients with HIV[@R138] did show an augmented immunogenic response following combined vaccination.

Pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD for the following considerations: (1) The increased risk of non-invasive and invasive pneumococcal disease in patients with AIIRD.[@R1] (2) Good efficacy, immunogenicity and a favourable safety profile of pneumococcal vaccines (with the exception of patients with CAPS). (3) In line with the present recommendations of the CDC[@R87] and the ESCMID.[@R135] Given the insufficient evidence for the efficacy of the combination of PCV13 and PPSC23, the choice and sequence of pneumococcal vaccination should be in concordance with local guidelines.

Hepatitis A vaccination {#s3-3}
-----------------------

### Efficacy---immunogenicity---safety {#s3-3-1}

Hepatitis A virus (HAV) vaccine, an inactivated vaccine, is very efficacious in preventing hepatitis A.[@R140] There are however no studies on the efficacy of HAV vaccination in patients with AIIRD. All three studies on immunogenicity HAV vaccination in patients with AIIRD have been published after the 2011 version EULAR recommendations[@R2] and SLR[@R142] ([table 9](#T9){ref-type="table"}).

###### 

Efficacy, immunogenicity and safety of hepatitis A vaccination in patients with AIIRD

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author +ref.          Year   Study design      No. cases           Efficacy   Immunogenicity                                                                    Safety                                                 Influence of IS on eff./imm.                                   LoE        
  --------------------------- ------ ----------------- ------------------- ---------- --------------------------------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------- ----- ---- ----
  Rosdahl[@R146]              2018   Cohort            69 RA\              --         Reduced in RA                                                                     No SAE\                                                --                                                             --    2b   4
                                                       58 HC                                                                                                            Mild systemic AE in 17% (HC and RA combined)                                                                                     

  Askling[@R145]              2014   Cohort            53 RA:\             --         Seroprotection in 10% after 1 month, 83% at month 7 (1 month after second dose)   One meningoencephalitis 2.5 weeks after second dose\   Possibly reduced on MTX                                        --    2b   4
                                                       15 anti-TNF\                                                                                                     Mild AE in 2                                                                                                                     
                                                       21 anti-TNF +MTX\                                                                                                                                                                                                                                 
                                                       17 MTX                                                                                                                                                                                                                                            

  Van den Bijllaardt[@R147]   2013   Cohort\           173 IS-treated:\    --                                                                                           --                                                     Reduced imm. on anti-TNF in multivariate regression analysis   --    2b   --
                                     (retrospective)   31 anti-TNF\                                                                                                                                                                                                                                      
                                                       123 DMARD\                                                                                                                                                                                                                                        
                                                       19 Other                                                                                                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AIIRD, autoimmune inflammatory rheumatic disease; DMARD, disease-modifying antirheumatic drug; eff., efficacy; HC, healthy control; imm., immunogenicity; IS, immunosuppressives; LoE, Level of evidence; MTX, methotrexate; No., number; RA, rheumatoid arthritis; ref., reference; (S)AE, (serious) adverse event; Saf., safety; TNF, tumor necrosis factor.

In healthy persons, the HAV vaccine is highly immunogenic, resulting in seroprotection in ≥95% only 1 month after the first vaccine dose.[@R143] In patients with RA, it has been shown to be less immunogenic. The percentage of seroprotected patients with RA after 1 month varied between 10%[@R145] and 60%--68%[@R146] in two studies that used different methods. A three-dose schedule (0, 1 and 6 months or 0 (double dose) and 6 months) resulted in 99% seroconversion in patients with RA after 12 months.[@R146] A double dose of vaccine at baseline did not result in an improved seroconversion rate after 1 month, compared with the usual dose (68% vs 60%).[@R146]

In terms of safety, there are no data on the influence of vaccination on activity of the underlying AIIRD. Adverse events were generally mild, and reported in up to 17% of patients.[@R145] Askling *et al* reported one case of meningoencephalitis which occurred in a patient with an RA 2.5 weeks after the second dose of HAV vaccine.[@R145]

### Influence of immunomodulating agents {#s3-3-2}

Using a cut-off for seroprotection of anti-HAV ≥10 mIU/mL instead of 20 mIU/ml, significantly more patients with RA using only an anti-TNFα agent (73%, n=15) reached seroprotection than those using a combination of anti-TNF and MTX (15%, n=21) or MTX alone (6%, n=17).[@R145] In a study of 173 immunosuppressive-treated patients (31 anti-TNF, 123 classic DMARD and 19 other), the use of anti-TNF was associated with lower seroprotection rates in a multivariate logistic regression analysis (see [table 9](#T9){ref-type="table"}).[@R147]

### Summary and clinical implications {#s3-3-3}

Since a single dose of HAV vaccine does not seem to afford sufficient protection in a substantial percentage of patients with AIIRD, it is recommended to administer a second dose of vaccine 6 months after the first and to determine postvaccination antibody titres. If this is not possible, as in the case of a last-minute traveller, it should be borne in mind that a patient with AIIRD may not be protected after a single dose of HAV vaccine. Passive immunisation for the specific journey may be considered.

Hepatitis B vaccination {#s3-4}
-----------------------

### Efficacy---immunogenicity---safety {#s3-4-1}

The incidence of hepatitis B virus (HBV) infections has markedly decreased in countries where HBV vaccination is routinely implemented.[@R148] Although no antibody level gives complete protection against transient infection, there is a clear association between antibody level and risk of HBV infection.[@R149] In general, a level of antihepatitis B surface antigen ≥10 mIU/ml is considered protective.

Up to the previous version of recommendations, a total of four studies reported on the immunogenicity of HBV vaccination in patients with RA,[@R150] SLE,[@R151] AS[@R152] and Behçet's disease.[@R153] One additional study in patients with RA had been published since then ([online supplementary table S1](#SP1){ref-type="supplementary-material"}).[@R154]

10.1136/rmdopen-2019-001035.supp1

This recent study, including 46 patients with RA and 9 HCs, reported a significantly lower percentage of patients versus HCs reaching seroprotective antibody levels (64% in patients vs 100% in HCs).[@R154] Another controlled study from 2005, with 13 patients with Behçet's disease and 15 HCs reported no difference in immunogenicity of the HBV vaccine.[@R153] A response to the vaccine was demonstrated in all remaining studies on HBV vaccination in patients with AIIRD that did not include a control group[@R150] ([online supplementary table S1](#SP1){ref-type="supplementary-material"}).

The HBV vaccine did not lead to changes in overall disease activity in patients with RA and Behçet's disease.[@R150]

### Influence of immunomodulating agents {#s3-4-2}

A severely hampered antibody response to HBV vaccination was noted in patients with AS treated with TNF-blocking agents.[@R152]

### Summary and clinical implications {#s3-4-3}

HBV vaccine should be administered to patients with AIIRD at risk of infection, for example, medical personnel, patients having an infected family member, intravenous drug users, men who have sex with men, and patients travelling to or residents from endemic countries. It is advised to determine vaccination response. For non-responders several strategies are available to try to reach seroprotection. A booster vaccination or passive immunisation should be considered for an unvaccinated patient or a patient with insufficient response exposed to HBV. See recommendations of the CDC via <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf>.

Tetanus toxoid vaccination {#s3-5}
--------------------------

### Efficacy---immunogenicity---safety {#s3-5-1}

The efficacy of tetanus toxoid vaccination in the prevention of tetanus has never been studied in a vaccine trial. The incidence of tetanus has been shown to decrease dramatically in vaccinated populations,[@R155] although this was not specified for the AIIRD population. The protective antibody level for tetanus is generally considered to be ≥0.1 IU/mL. Tetanus is extremely rare in fully immunised adults who received their last dose of vaccine within the preceding 10 years.

Reports on immunogenicity of tetanus toxoid vaccination in patients with RA showed satisfactory antibody responses.[@R9] Most studies in patients with SLE reported adequate response rates.[@R102] One small study from 1980 including nine patients with SLE and nine HCs showed a diminished response in the patients with SLE, with a blunted response in three of them.[@R160]

Most studies did not report on safety of tetanus toxoid vaccination. One randomised controlled trial (RCT) showed a higher incidence of mild/moderate adverse events after combined tetanus toxoid and pneumococcal vaccination in patients with RA on MTX who recently started the use of tocilizumab, compared with patients with RA on MTX only ([online supplementary table S2](#SP1){ref-type="supplementary-material"}).[@R112]

### Influence of immunomodulating agents {#s3-5-2}

Rituximab administered 24 weeks before vaccination did not affect response to the tetanus toxoid vaccine in patients with RA.[@R90] An RCT in 54 patients with RA on MTX who started tociluzimab 3 weeks before tetanus toxoid vaccination, and 27 RA MTX disease controls, showed no difference in immunogenicity of the tetanus toxoid vaccine between groups. However, there were only three patients in the tocilizumab + MTX group who did not have a seroprotective antibody level at baseline. Two out of these three patients reached a protective level 5 weeks after vaccination.[@R112]

An observational study on immunogenicity of pneumococcal, tetanus toxoid and *H. influenzae* type B vaccine in 73 patients with SLE reported a trend towards a lower response in patients on glucocorticoids and azathioprine, which was not specified for tetanus toxoid vaccination.[@R102]

### Summary and clinical implications {#s3-5-3}

As satisfactory immune responses were observed in patients with AIIRD following tetanus toxoid vaccination, mostly similar to the response in HCs, and no serious adverse events have been reported, the updated EULAR recommendations conclude that patients with AIIRD should receive tetanus toxoid vaccination according to national recommendations for the general population. Since no data are available on efficacy or immunogenicity of tetanus toxoid vaccination in patients who received B cell depleting therapy within the preceding 6 months, passive immunisation with tetanus immunoglobulins should be considered in these patients in case of an event with high risk of acquiring tetanus, when the vaccine would otherwise be indicated, according to expert opinion.

Herpes zoster vaccination {#s3-6}
-------------------------

### Efficacy---immunogenicity---safety {#s3-6-1}

Up to the previous recommendations, no data were available on herpes zoster vaccination in patients with AIIRD. Since 2010 seven relevant studies have been published ([table 10](#T10){ref-type="table"}).

###### 

Efficacy, immunogenicity and safety of live-attenuated herpes zoster vaccination in patients with AIIRD

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author +ref.   Year    Study design                      No. cases                              Efficacy                                                     Immunogenicity                                                               Safety                                                                                                                         Influence IS on eff./imm.                                                  LoE        
  -------------------- ------- --------------------------------- -------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ----- ---- ---
  Winthrop[@R170]      2017    RCT                               55 RA MTX+TFC\*\                       --                                                           Similar CMI response. Trend towards higher humoral response MTX+TFC          3 SAE in MTX-TFC group versus 0 in MTX+PCB:\                                                                                   See column immunogenicity.                                                 --    2b   4
                                                                 57 RA MTX+PCB\*                                                                                                                                                                  one cholangitis,\                                                                                                                                                                                                    
                                                                                                                                                                                                                                                  one bronchitis and\                                                                                                                                                                                                  
                                                                                                                                                                                                                                                  one disseminated primary varicella in seronegative patient.\                                                                                                                                                         
                                                                                                                                                                                                                                                  Mild AE no difference.                                                                                                                                                                                               

  Russell[@R173]       2015    RCT                               206 GC vacc.\                          --                                                           Higher postvacc. humoral response in vacc.                                   More injection-site AE and headache in vacc. Other systemic and serious AE: no difference.                                     No influence of limited daily GC dose                                      --    2b   4
                                                                 (25% PMR)\                                                                                                                                                                                                                                                                                                                                                                                            
                                                                 100 GC PCB-vacc\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                 (31% PMR)\                                                                                                                                                                                                                                                                                                                                                                                            
                                                                 Mostly no AIIRD.\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                 \>10--20 mg: n=39                                                                                                                                                                                                                                                                                                                                                                                     

  Koh[@R169]           2018    Cohort                            41 RA\                                 --                                                           Lower CMI response in RA. Similar humoral response.                          No SAE. Mild systemic AE in 11.6% of all participants.\                                                                        --                                                                         --    2b   4
                                                                 28 OA                                                                                                                                                                            6 RA flares during 12 weeks postvacc. Median Disease Activity Index unchanged.                                                                                                                                       

  Zhang[@R167]\        2012\   Cohort (retrospective database)   Total: 463 541\                        Lower incidence of HZ in vacc. patients.\                    --                                                                           \<42 of vacc: HZ incidence decreased, no cases of hospitalised meningitis or encephalitis, no HZ in patients using biologics   Lower HZ incidence in vacc. patients using biologics, DMARDs or GC alone   2b    --   4
  and Yun[@R168]       2017                                      Vacc: 18 683 (4.0%)\                   Rapid decline difference incidence rate vacc. and unvacc.\                                                                                                                                                                                                                                                                                                     
                                                                 Vacc on biologics: 633\                6 years postvacc: no longer significant.                                                                                                                                                                                                                                                                                                                       
                                                                 7780 vaccinated patients in analysis                                                                                                                                                                                                                                                                                                                                                                  

  Guthridge[@R171]     2013    Cohort                            10 SLE\                                --                                                           Similar proportion of subjects with 50% increase in CMI measures postvacc.   No difference.\                                                                                                                --                                                                         --    2b   4
                                                                 10 HC                                                                                                                                                                            No flares.                                                                                                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Tofacitinib or placebo was started 2--3 weeks postvaccination.

†Patients with rheumatoid arthritis (n=292 169), psoriasis (n=89 565), psoriatic arthritis (n=11 030), ankylosing spondylitis (n=4026) and/or inflammatory bowel disease (n=66 751).

AIIRD, auto-immune inflammatory rheumatic disease; CMI, cell-mediated immunity; DMARD, disease-modifying antirheumatic drug; eff., efficacy; GC, glucocorticoids; HC, healthy controls; HZ, herpes zoster; imm., immunogenicity; IS, immunosuppressives; LoE, Level of evidence; MTX, methotrexate; No., number; OA, osteoarthritis; PCB, placebo; PMR, polymyalgiarheumatica; RA, rheumatoid arthritis; RCT, randomised controlled trial; ref., reference; (S)AE, serious adverse event(s); Saf., safety; SLE, systemic lupus erythematosus; TFC, tofacitinib; vacc., vaccinated.

Currently, two different vaccines are available for the prevention of herpes zoster in varicella-zoster virus (VZV)-seropositive healthy adults above the age of 50 years: one is a live-attenuated vaccine and the other is an adjuvanted subunit (non-live) vaccine. All studies on zoster vaccination in patients with AIIRD have been performed using the live-attenuated zoster vaccine. This vaccine has been shown to decrease the risk of herpes zoster in adults above the age of 50 years by 38%--70%,[@R161] with lowest efficacy in those above 70 years.[@R161] Of note, the AS01 adjuvanted subunit (non-live) vaccine has recently been shown to be safe and more efficacious than the live-attenuated vaccine in healthy adults above the age of 50 and 70 years.[@R161] Vaccine efficacy ranged between 91% and 98% and did not significantly differ between age groups.[@R163] Of note, safety of the adjuvant system AS01, which contributes to the generation of a particularly strong cellular immune response,[@R165] has not yet been determined in patients with AIIRD.

Vaccination with the live-attenuated zoster vaccine was associated with a reduced incidence of herpes zoster in patients with immune-mediated diseases (RA, psoriatic arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel diseases) over 60 years of age, as reported in a large retrospective database study by Zhang *et al*. In total, 7780 vaccinated and over 800 000 unvaccinated patients were included in their analysis.[@R167] A rapid decline in vaccine efficacy was observed in the same study population. Six years after vaccination, the difference in herpes zoster incidence between groups of vaccinated and unvaccinated subjects was no longer significant.[@R168]

Immunogenicity of the live-attenuated zoster vaccine has been investigated in patients with RA[@R169] and SLE.[@R171] Both patient groups were able to mount cell-mediated immune responses to the vaccine,[@R169] which is crucial for the protection against herpes zoster.[@R172] However, live-attenuated zoster vaccination resulted in lower cell-mediated immunity in patients with RA (n=41) than in controls (n=28).[@R169] Because no correlate of protection for herpes zoster infection is known, and methods for assessing herpes zoster immunity are not uniform, interpretation and comparison of studies is difficult.

Disease activity of the underlying AIIRD did not seem to be affected by live zoster vaccination, but numbers of analysed patients are low.[@R169] In a study in patients with RA, who were randomised to receive tofacitinib (n=55) or placebo (n=57) 2--3 weeks following vaccination, three serious adverse events were observed in the tofacitinib group versus none in the placebo group. Of note, one case of disseminated primary varicella occurred in a patient who was VZV-seronegative at baseline.[@R170] In the retrospective database study by Zhang *et al*, the zoster vaccine did not seem to induce infection within 42 days after vaccination. On the contrary: a reduced incidence of herpes zoster was seen in the vaccinated patients. No cases of hospitalised meningitis or encephalitis were identified in this period.[@R167]

### Influence of immunomodulating agents {#s3-6-2}

The favourable effect of vaccination on herpes zoster incidence in patients with autoimmune diseases is present regardless of medication use, including biologics (used by 633 vaccinated patients), as reported in the same large database study by Zhang *et al*.[@R167] A daily dose of 5--20 mg of corticosteroids in a heterogeneous patient group (206 patients received zoster vaccination, of whom 25% were patients with polymyalgia rheumatica) did not seem to affect humoral immune response to live-attenuated zoster vaccination. Unfortunately, effect on cell-mediated immune response was not reported.[@R173] Zoster vaccination resulted in a similar cell-mediated response in patients with RA who started the use of tofacitinib or placebo 2--3 weeks after vaccination (see [table 10](#T10){ref-type="table"}).[@R170]

### Summary and clinical implications {#s3-6-3}

Although large prospective trials that are sufficiently powered for assessing safety are lacking, the safety and efficacy profile of the live-attenuated zoster vaccine seem to be favourable for VZV-seropositive patients with AIIRD. However, the vaccine contains live-attenuated virus and, therefore, should still be considered with caution in the immunocompromised patient. Before administering the zoster vaccine, it is advisable to affirm the VZV-seropositive status of the patient. In case of a VZV-seronegative patient, a less potent VZV vaccine approved for preventing primary varicella in children may be considered. Based on expert opinion, the zoster vaccine is preferably administered 4 weeks prior to initiation and not during treatment with biologics and targeted synthetic DMARDs.

As noted earlier, the novel non-live AS01 adjuvanted subunit vaccine has been shown to be more efficacious than the live-attenuated vaccine in healthy adults above the age of 50--70 years. Whether this also holds true for the AIIRD population and whether the adjuvant system AS01 is safe in this patient group, is most interesting and warrants further investigation.

Yellow fever vaccination {#s3-7}
------------------------

### Efficacy---immunogenicity---safety {#s3-7-1}

The yellow fever vaccine is a live-attenuated vaccine. Several cases of visceral dissemination of yellow fever of the vaccine type have been reported, with clinical features similar to wild type yellow fever, including high mortality.[@R174] The vaccine is therefore generally contraindicated in immunocompromised patients[@R177] ([online supplementary table S3](#SP1){ref-type="supplementary-material"}).

Only limited observational studies have been published on yellow fever vaccination in patients with AIIRD, mostly concerning revaccination (see [online supplementary table S3](#SP1){ref-type="supplementary-material"} for details). The reported immunogenicity results are mainly adequate, and similar as in HC.[@R177]

A study of 34 glucocorticoid-treated patients (among whom 9 were patients with RA and 14 with chronic inflammatory conditions, revaccination in 44%) and 68 HC, reported more moderate and severe local reactions in patients (12% vs 2%).[@R179] No serious systemic adverse events of yellow fever vaccination were reported in the previously mentioned studies in patients with AIIRD. As the vaccine has been contraindicated in immunocompromised patients for years, numbers of studies and included patients are however very low and, as stated, most patients were revaccinated. Of note, lethal outcomes of fellow fever vaccination have been reported in immunocompromised patients, including a female patient with RA and SLE, who was possibly treated with glucocorticoids and MTX.[@R181]

### Influence of immunomodulating agents {#s3-7-2}

Due to the heterogeneous populations of the small studies on yellow fever vaccination in patients with AIIRD, it is difficult to discern the separate influences of different immunosuppressive agents. In a study of corticosteroid-treated patients, of whom 44% were vaccinated for yellow fever earlier in life, seroprotection against yellow fever was reached in all 20 analysed patients. A trend towards a lower yellow fever antibody response was observed in anti-TNFα-treated patients with RA (n=17) compared with HC (n=15).[@R180]

### Summary and clinical implications {#s3-7-3}

Reported immunogenicity results of yellow fever revaccination among patients with AIIRD are mainly adequate and similar as in HC. However, the available data on the safety of yellow fever vaccination in this group are very limited, and potential sequelae are serious (including death). Patients with AIIRD under immunosuppression should, therefore, avoid yellow fever vaccination in general. Temporarily withholding immunosuppressive therapy may be considered for patients with AIIRD travelling to endemic countries.

Human papillomavirus vaccination {#s3-8}
--------------------------------

### Efficacy---immunogenicity---safety {#s3-8-1}

Data on the efficacy of human papillomavirus (HPV) vaccination originate from vaccine trials in HCs that investigate the capacity of HPV vaccination to prevent premalignant lesions. A vaccine efficacy of 66% to prevent cervical intraepithelial neoplasia grade III was reported in a bivalent (HPV types 16 and 18) HPV vaccine trial after 4.5--10 years of follow-up.[@R182]

The correlation between the level of anti-HPV antibodies and protection against the development of cervical carcinoma is not known, since there are no reports on cervical carcinoma in vaccinated subjects. The level of seroprotection is based on comparison with naturally infected subjects.[@R183]

To date, no studies on the efficacy of HPV vaccination to prevent malignancies or premalignant lesions in the AIIRD population have been published, but there are studies on HPV vaccine immunogenicity in patients with AIIRD, all published after 2010 ([online supplementary table S4](#SP1){ref-type="supplementary-material"}). All but one study, performed in patients with juvenile idiopathic arthritis (JIA),[@R184] include patients with SLE and used a quadrivalent (HPV types 6, 11, 16 and 18) vaccine.[@R185] Seroconversion rates in patients were high and usually similar to those of healthy subjects, although two studies reported a lower geometrical mean titre for HPV 16 in patients with SLE after 5 years of follow-up,[@R185] and also for patients with JIA,[@R184] compared with HCs.

Rates of vaccine adverse events similar to HCs were reported for both patients with SLE[@R188] and patients with JIA.[@R184] Disease activity after vaccination was stable.[@R184]

### Influence of immunomodulating agents {#s3-8-2}

Mok *et al* reported that anti-HPV titres were lower in vaccinated patients with SLE using immunsosuppressive agents, especially in those receiving a combination of mycophenolate mofetil (MMF) and glucocorticoids.[@R188] After 5 years of follow-up it was noted that patients with SLE that no longer were anti-HPV seropositive received significantly longer and higher doses of glucocorticoids and MMF than those with persistent seropositivity.[@R185]

### Summary and clinical implications {#s3-8-3}

Immunogenicity of HPV vaccination in the AIIRD population is high and, in the majority of studies, similar to that in HCs. The vaccine appears to be safe in patients with AIIRD. Therefore, the vaccine is recommended for patients with AIIRD, in accordance with recommendations for the general population. Patients with SLE, in particular, are advised to receive HPV vaccination, since they were shown to be at high risk of contracting a genital HPV infection, including the serotypes that are considered to be high risk for developing cervical dysplasia.[@R190]

Tickborne encephalitis vaccination {#s3-9}
----------------------------------

### Efficacy---immunogenicity---safety {#s3-9-1}

The available tickborne encephalitis (TBE) vaccines are inactivated vaccines. The vaccine is highly immunogenic in the general adult population.[@R195] Excellent effectiveness of TBE vaccination in prevention of TBE was demonstrated in an Austrian study.[@R196] Nonetheless, cases of vaccine failure have been reported, which occurred mainly in older or immunocompromised persons[@R197].

To date, only one study on vaccination against TBE in patients with AIIRD has been published ([online supplementary table S5](#SP1){ref-type="supplementary-material"}). This Swedish study by Hertzell *et al* enrolled 65 patients with RA and 1 patient with AS on anti-TNF (n=16), a combination of MTX and anti-TNF (n=36) or MTX alone (n=14). Four doses of vaccine instead of three were offered to patients and HCs ≥60 years of age. One month after the last dose of vaccine, 39% of the patients and 79% of the HCs had developed protective levels of neutralising TBE antibodies. The difference was statistically significant. An extra dose of vaccine in patients with an undetectable antibody level at month 13 resulted in seroprotection in 4 out of 10 patients, all of whom were older than 60 years. No serious adverse events occurred.[@R198]

### Influence of immunomodulating agents {#s3-9-2}

In the study by Hertzell *et al*, regarding only patients ≥60 years of age, it seemed that a lower percentage of those treated with a combination of MTX and anti-TNF reached seroprotective anti-TBE levels than those treated with MTX or anti-TNF alone (25% vs 38%--40%).[@R198]

### Summary and clinical implications {#s3-9-3}

Although the updated recommendations do not specifically provide recommendations regarding TBE vaccination, an overarching principle states that non-live vaccines can be administered to patients with AIIRD, including during their use of glucocorticoids and DMARDs. The only available study on TBE vaccination in the AIIRD patient population showed a diminished immunogenicity response in these patients. As such, determining TBE-antibody levels after the last vaccine dose and, if necessary, giving an extra dose of vaccine may be considered.

Discussion {#s4}
==========

This SLR summarises the available data on efficacy, immunogenicity and safety of vaccination in patients with AIIRD, including patients with AIIRD using immunomodulating agents. Since the first version of EULAR recommendations and accompanying SLR on vaccination of adult patients with AIIRD were published in 2011,[@R2] there has been a large expansion in the amount of available evidence on this topic, necessitating an update. By defining four research questions, we were able to address incidence/prevalence of VPIs, efficacy, immunogenicity and safety of vaccination, as well as the influence of immunomodulating agents on vaccine efficacy/immunogenicity in patients with AIIRD. To enable the presentation of a clear overview of the large amount of available data, the evidence on the incidence and prevalence of VPI diseases in patients with AIIRD was presented in a separate SLR, which was submitted for publication simultaneously with this report. The literature search for the fourth research question, dealing with the effect of vaccinating household members of patients with AIIRD on the occurrence of VPI in these patients and household members (including newborns), did not result in finding any relevant studies. Therefore, the recommendation encouraging household members of patients with AIIRD to receive vaccines according to national guidelines with the exception of oral polio vaccine, as formulated in the updated recommendations, is based on expert opinion. This recommendation follows guidelines of international societies such as the Infectious Diseases Society of America.[@R199] Also the recommendation of avoiding live-attenuated vaccines during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy is based on expert opinion. This recommendation is in line with the EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.[@R200]

One strength of our current approach, compared with the 2011 SLR, is the clear separation between efficacy and immunogenicity of vaccination, allowing a just interpretation of the data by readers. When assessing the different vaccines, evidence on efficacy, defined as the capacity of a vaccine to prevent infection, was considered to be of higher quality than evidence on immunogenicity, which refers to the capacity of vaccines to induce humoral and/or cellular immune responses. Unfortunately, because of the necessarily large sample size, using a clinical end point was essentially infeasible for some groups of AIIRD and/or vaccines. Consequently, only a small number of studies used a clinical end point.

It is important to note that although a large number of articles was included, for certain AIIRDs, vaccines and immunomodulating treatments the number of publications was still very limited. The majority of studies was performed in patients with RA and SLE. Results in these patient groups cannot uncontestedly be extrapolated one on one to patients with other AIIRDs.

Regarding safety of vaccination in the AIIRD population, both the occurrence of adverse events and influence on underlying disease of vaccination were assessed. Although since 2011 the amount of available evidence has considerably grown, studying safety of vaccination in patients with AIIRD remains a challenge. While vaccination did not lead to significant harms in the large majority of the included studies, these studies were too small or not properly designed to be able to detect the occurrence of rare adverse events.

In conclusion, evidence on efficacy, immunogenicity and safety of vaccination in patients with AIIRD (including those using immunomodulation agents), from October 2009 to August 2018, was systematically reviewed to provide a basis for updated evidence-based recommendations for vaccination in patients with AIIRD,[@R3] in order to aid physicians, nurses and other health professionals dealing with questions regarding vaccination in patients with AIIRD in daily clinical practice.

CR and VF contributed equally.

**Contributors:** CR, in collaboration with SvA, reviewed articles on efficacy, immunogenicity and safety of vaccination for influenza, hepatitis A, hepatitis B, tetanus toxoid, herpes zoster, yellow fever and tickborne encephalitis in patients with AIIRD, and drafted the first version of the manuscript. VF, in collaboration with OE, performed the literature search and reviewed articles on vaccination in patients with AIIRD on the various immunomodulating therapies. MH reviewed articles on efficacy, immunogenicity and safety of vaccination of human papillomavirus vaccination in patients with AIIRD. OE initiated the project, reviewed articles on efficacy, immunogenicity and safety of vaccination for pneumococcal disease in patients with AIIRD, and wrote the paragraphs on pneumococcal vaccination. All authors collaborated in discussions during two meetings, and read and approved the final manuscript.

**Funding:** This project was supported by EULAR.

**Competing interests:** KW reports personal fees from Pfizer, during the conduct of the study; grants and personal fees from Biotest, CSL Behring, personal fees from LFB, Grifols, Baxter, Roche, Octapharma, grants from BMS, outside the submitted work. AM reports grants and personal fees from ABBVIE, Pfizer, BMS, UCB, MERCK, during the conduct of the study. MD reports grants and personal fees from PFIZER, ABBVIE, UCB, NOVARTIS, LILLY, MERCK, ROCHE, grants from BMS, outside the submitted work. OE reports grants and personal fees from Pfizer, Abbvie, Roche, Janssen, personal fees from Novartis and Lilly. All other authors have no conflicts of interests to declare.

**Patient consent for publication:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data availability statement:** All data relevant to the study are included in the article or uploaded as supplementary information.
